Monograph Details
|
|
Neoplasms
> Cytoprotective agents
|
|
ZINECARD |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Chelating agent. |
| Generic Name |
|
Dexrazoxane 250mg, 500mg; per vial; pwd for IV infusion after reconstitution and dilution. |
| Indications |
|
To reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300mg/m2 and will continue to receive doxorubicin therapy to maintain tumor control. |
| Children |
|
Not recommended. |
| Adults |
|
Give by slow IV push or rapid drip IV infusion. Doxorubicin should be administered within 30 minutes after starting Zinecard infusion. Administer in 10:1 ratio (eg, 500mg/m2 Zinecard: 50mg/m2 doxorubicin). Renal impairment (CrCl <40mL/min): reduce ratio to 5:1 (eg, 250mg/m2 Zinecard: 50mg/m2 doxorubicin). Hepatic impairment: may need to reduce doxorubicin dose, therefore Zinecard dose must be reduced (maintaining 10:1 ratio). |
| Contraindications |
|
Chemotherapy regimens that do not contain an anthracycline. |
| Precautions |
|
Not recommended for use with initiation of doxorubicin. Renal or hepatic impairment. Monitor cardiac function and for myelosuppression; obtain CBCs frequently. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Adverse Reactions |
|
Inj site pain, myelosuppression, possible secondary malignancies (see literature). |
| How Supplied |
|
Single-use vial—1 (w. diluent) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
